Home » Stocks » IMRA

IMARA Inc. (IMRA)

Stock Price: $14.04 USD -0.01 (-0.07%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $14.03 -0.01 (-0.07%) Jan 22, 7:50 PM
Market Cap 244.40M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 17.35M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $14.04
Previous Close $14.05
Change ($) -0.01
Change (%) -0.07%
Day's Open 14.04
Day's Range 13.80 - 14.16
Day's Volume 85,002
52-Week Range 13.40 - 54.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biophar...

Benzinga - 2 weeks ago

Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of...

GlobeNewsWire - 1 month ago

Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment

GlobeNewsWire - 1 month ago

BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...

GlobeNewsWire - 2 months ago

Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs Brings 25 years of experienc...

Seeking Alpha - 2 months ago

IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Patient Dosing Underway in Phase 2b clinical trials of IMR-687  in sickle cell disease and beta-thalassemia

GlobeNewsWire - 2 months ago

BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...

GlobeNewsWire - 3 months ago

Forte is the first clinical trial of IMR-687 in patients with beta-thalassemia and follows the initiation of Ardent Phase 2b clinical trial of IMR-687 in sickle cell disease Forte is the first...

GlobeNewsWire - 4 months ago

Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global Healthcare Conference Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley 18th Annual Global He...

GlobeNewsWire - 4 months ago

BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patien...

Seeking Alpha - 5 months ago

IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial

GlobeNewsWire - 5 months ago

Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease Highly selective, potent, small molecule...

GlobeNewsWire - 5 months ago

BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patien...

GlobeNewsWire - 5 months ago

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patien...

Zacks Investment Research - 6 months ago

Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

Other stocks mentioned: COWN, GAN, GTY
GlobeNewsWire - 6 months ago

BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patien...

CNN Business - 6 months ago

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Nova...

Other stocks mentioned: BIO, FMTX, KROS, PCVX, RNA, RPTX, XBI, ZNTL
GlobeNewsWire - 6 months ago

Company expands program to award 25 grants totaling $125,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Company expan...

GlobeNewsWire - 6 months ago

BOSTON, Mass., June 24, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat...

Market Watch - 7 months ago

Imara Inc. IMRA, +12.66% announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment.

GlobeNewsWire - 7 months ago

Showed statistically significant increase in red blood cells containing fetal hemoglobin (F-cells) and dose-dependent increase in fetal hemoglobin percentage in high-dose group after 24 weeks ...

About IMRA

Imara, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, which is an oral, once-a-day therapeutic for the treatment of sickle cell disease and b-thalassemia. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
IPO Date
Mar 12, 2020
CEO
Dr. Rahul D. Ballal Ph.D.
Employees
16
Stock Exchange
NASDAQ
Ticker Symbol
IMRA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for IMARA Inc. stock is "Strong Buy." The 12-month stock price forecast is 41.33, which is an increase of 194.37% from the latest price.

Price Target
$41.33
(194.37% upside)
Analyst Consensus: Strong Buy